Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 5, 2006, Pages

  Ballard, Clive G ^a   Waite, Jonathan ^b   Birks, Jacqueline ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85021214925     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003476.pub2     Document Type: Review

References (181)

1. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jocoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005;330(874):DOI: 10.1136/bmj.38369.459988.8F.
2. Breder C, Swanink R, Marcus R, Kostic D, Iwamoto T, Carson W, McQuade R, Bristol-Myers Squibb Company, Wallingford, CT, USA. Dose-Ranging Study of Aripiprazole in Patients With Dementia of Alzheimer's Disease. NeuroBiology of Aging 2004;25(S2):190.
3. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. The Journal of Clinical Psychiatry 2003;64(2):134-43.
4. Brodaty H, Clarnette R, Ames D, Snowdon J, Woodward M, Kirwan J, Lee E, Lyons B, Grossman F. Psychological symptoms are improved with risperidone in patients with dementia-related psychosis. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002:Abstract No 330.
5. Brodaty H, Clarnette R, Ames D, Snowdon, Woodward M, Kirwan J, Lee E, Lyons B, Grossman F. Risperidone in the treatment of agitation, aggression and psychosis of dementia. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002:Abstract No 289.
6. Brodaty H, Grossman F, Bruynseels J, Lyons B. Risperidone in the treatment of agitation and psychosis of dementia. International Psychogeriatrics 2001;13(Suppl 2):S108.
7. Clarnette R, Brodaty H, Ames D, Snowdon J, Lee E, Woodward M, Kirwan J, Lyons B, Grossman F. Psychological symptoms are improved with risperidone in patients with dementia-related psychosis. Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (International Journal of Neuropsychopharmacology), June 23-27 2002, Montreal, Canada. 2002; Vol. 5, issue Suppl 1:S91.
8. Clarnette R, Brodaty H, Ames D, Snowdon J, Lee E, Woodward M, Kirwan J, Lyons B, Grossman F. Risperidone in the treatment of agitation, aggression and psychosis of dementia. Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (International Journal of Neuropsychopharmacology), June 23-27 2002, Montreal, Canada. 2002; Vol. 5, issue Suppl 1:S91.
9. Kirwan J, Brodaty H, Ames D, Snowdon J, Woodward M, Clarnette R, Lee E. Risperidone in the treatment of agitation and psychosis of dementia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
10. Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. Journal of Clinical Psychiatry, The 2004;65(10):1329-34.
11. Woodward M, Brodaty H, Lee E. Risperidone in the treatment of agitation and psychosis of dementia: A multicentre, double-blind, placebo controlled study. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva. 2002:255.
12. Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophrenia Bulletin 2003;29(1):73-80.
13. Ismail MS, Schneider LS, Tariot P, Dagerman KS, Davis S. NIMH Comparative Effectiveness of Antipsychotic Medications in Patients with Alzheimer's disease (CATIE-AD): Clinical course. NeuroBiology of Aging 2004;25(S2):P1-320, p 188.
14. Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia bulletin 2003;29(1):57-72.
15. Schneider LS, Tariot P, Lebowitz B. Health outcomes and effectiveness of atypical antipsychotics in outpatients with psychosis or agitation associated with AD. Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington, DC. 2000b.
16. Schneider LS, Tariot PN, Alexopoulos G, Davis K, Davis S, Jeste D, Katz I, Keefe R, LaVange L, Lebowitz B, Lyketsos C, Pollock B, Rabins P, Rosenheck R, Small G, Stroup S, Davis CE, Ferris S, Hsiao J, Krishnan R, Lieberman J, Mittelman M, Mohs R, Perkins D, Swartz M. Comparative Effectiveness of Antipsychotic Medications in patients with Alzheimer's Disease. Clinicaltrialsgov 2000a.
17. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenbeck RA, Small GW, Lebowitz B, Lieberman JA. National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) Alzheimer disease trial methodology. American Journal of Geriatric Psychiatry 2001;9(4):346-60.
18. Anon. Aripiprazole improves psychotic symptoms in Alzheimer's disease outpatients. http://mblcommunications.com/newsdetail.php3?id=90 2003h.
19. Anon. Safety experience in elderly patients with psychosis associated with Alzheimer's disease. http://www.healthscout.com/rxdetail/68/101/3/main.html 2003g.
20. Anon. Study of aripiprazole in the treatment of patients with psychosis associated with dementia of the Alzheimer's type. Clinicaltrials.gov 2003b.
21. Breder C, De Deyn PP, Jeste DV, Auby P, Carson W, Marcus R, Kujawa M, McQuade RD, Schneider LS, Mintzer J. Aripiprazole for psychosis of Alzheimer's disease. NCDEU Poster abstacts 2003, issue Poster session II-65.
22. Darves B. Aripiprazole Effective in Reducing Psychotic Symptoms Associated with AD-related Dementia. Annual Meeting of the American Association for Geriatric Psychiatry, Honolulu, Hawai, March 2003. 2003.
23. De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C. Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease: A Randomized, Placebo-Controlled Study. Journal of Clinical Psychopharmacology 2005;25(5):463-7.
24. De Deyn PP, Jeste D, Aubey P, Goyvaerts H, Breder C, Schnieder L, Mintzer J. Aripiprazole for psychosis of Alzheimer's disease. IPA, 11th International Congress, Chicago, USA 18 August 2003. 2003:PA-010.
25. Mintzer J, De Deyn PP, Jeste D. Aripripazole in dementia of the Alzheimer's Type. The International Psychogeriatric Association European Regional Meeting, Geneva, Switzerland, 1-4 April 2004. 2003.
26. Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacology Bulletin 1995;31:534.
27. Clark W, Street J, Sanger T, Breier A. Reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville. 2000e:176.
28. Clark WS, Street J, Gannon KS, Sanger T, Breier A. Reduction of psychotic symptoms in patients with lewy-body-like-symptoms treated with olanzapine. European Journal of Neurology 1999a;6(Suppl 3):27.
29. Clark WS, Street J, Gannon KS, Sanger T, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. Journal of the European College of Neuropsychopharmacology 1999c;9(suppl 5):S332.
30. Clark WS, Street J, Gannon KS, Sanger T, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. European Journal of Neurology 1999b;6(Suppl 3):115.
31. Clark WS, Street J, Sanger T, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville. 2000a:144.
32. Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Journal of Clinical Psychiatry 2001a;62(1):34-40.
33. Clark WS, Street JS, Gannon KS, Sanger TM, Breier A. Reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine. Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada. 1999c:172.
34. Clark WS, Street JS, Gannon KS, Sanger TM, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. International Journal of Neuropsychopharmacology 2000a;3(Suppl 1):S357.
35. Clark WS, Street JS, Gannon KS, Sanger TM, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada. 1999b:172.
36. Clark WS, Street JS, Sanger TM, Breier A. Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia. International Journal of Neuropsychopharmacology 2000b;3(Suppl 1):S357.
37. Clark WS, Street JS, Sanger TM, Breier A, Cummings JL. Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia. Schizophrenia Research 2001b;49(1-2 Suppl):222.
38. Clark WS, Street JS, Sanger TM, Feldman PD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. Biological Psychiatry 2000c;47(Suppl):S162.
39. Clark WS, Street JS, Sanger TM, Feldman PD, Breier A. Reduction of psychotic symptoms in patients with Lewy body-like symptoms treated with olanzapine. Biological Psychiatry 2000d;47:163S.
40. Feldman PD, Clark WS, Breier A, Sanger TM, Street JS. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease. Schizophrenia Research 2001b;49(1-2 Suppl):227.
41. Kennedy J, Basson B, Zagar A, Clark W, Sanger T, Street J, Stauffer V, Bymaster F, Tollefson G. The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville. 2000g:175.
42. Kennedy JS, Basson BB, Zagar AJ, Clark WS, Sanger TM, Street JS, Stauffer VL, Bymaster FP, Tollefson GD. The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioural disturbances. Clinical Neuropsychological Assessment 2000f;1(6):42-3.
43. Kennedy JS, Basson BR, Zagar AJ, Gilmore JA, Wei H, Kinon BJ. The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances: continued improvement in quality of life despite weight change during olanzapine or haloperidol treatment. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25-29, Philadelphia. 2000c.
44. Kennedy JS, Clark WS, Street JS, Sanger TM, Breier A. Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia. Clinical Neuropsychological Assessment 2000d;1(6):53-4.
45. Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. International Journal of Geriatric Psychiatry 2001;16 Suppl 1:S71-7.
46. Slawson DC. Is olanzapine effective in the treatment of agitation/aggression and psychosis in patients with Alzheimer disease (AD)? [Commentary on Street JS, Clark WS, Gannon KS et al Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial Archives of General Psychiatry 2000;57: 968-76]. Evidence Based Practice 2001;4(1):5-6.
47. Street J, Clark KS, Gannon KS, Mitan S, Kadam D, Sanger T. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease. Journal of the European College of Neuropsychopharmacology 1999e;9(suppl 5):S331.
48. Street J, Clark S, Juliar B, Feldman P, Kadam D, Breier A. Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia. Journal of the European College of Neuropsychopharmacology 2000g;10(Suppl 4):S365-6.
49. Street J, Clark SW, Gannon KS, Mitan S, Kadman D, Sanger T, Tamura R, Tollefson GD. Effect of olanzapine on psychosis and behavioural disturbances associated with alzheimer's disease. Journal of the American Geriatrics Society 1999g;47:S89.
50. Street J, Clark WS, Gannon K, Mitan S, Kadam D, Sanger T, Tamura R, Tollefson GD. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disaese. Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada. 1999f:123.
51. Street J, Clark WS, Gannon KS, Mitan S, Kadman D, Famura R, Tollefson GD. Olanzapine in the treatment of psychosis and behavioural disturbances assocated with alzheimer's disease. Schizophrenia Research 1999a;1,2 & 3:298.
52. Street J, Clark WS, Gannon KS, Mitan S, Sanger T, Tollefson GD. Olanzapine reduces psychotic symptoms and behavioural disturbances associated with Alzheimer's disease. Schizophrenia Research 2000a;41(1):191.
53. Street J, Clark WS, Gannon KS, Sanger T, Breier A. Reduction of psychotic symptoms in patients with Lewy body-like symptoms treated with olanzapine. Journal of the European College of Neuropsychopharmacology 1999d;9(Suppl 5):S331-2.
54. Street J, Gannon K, Mitan S, Clark WS, Tollefson GD, Sanger T. Olanzapine reduces psychotic symptoms and behavioural disturbances associated with Alzheimer's disease. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11, Hamburg 1999b;Abstracts Volume II:72.
55. Street JS, Clark WS, Cummings JL, Kadam DL, Mitan SJ, Sanger TM, Bymaster FP, Tamura RN, Feldman PD, Gannon KS, Tollefson GD, Breier A. Olanzapine in the treatment of psychosis and behavioural disturbances associated with alzheimer's disease. Journal of Neurosurgery 2001c;187(Suppl 1):S57.
56. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A, HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry 2000b;57(10):968-76.
57. Street JS, Clark WS, Gannon KS, Mitan S, Sanger TM, Tollefson GD. Olanzapine in the treatment of psychosis and behavioral disturbances associated with alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20, Washington DC. 1999c.
58. Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer`s dementia. Biological Psychiatry 2000c;47(8):S162.
59. Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer's dementia. Schizophrenia Research 2001a;49(Suppl 1-2):246.
60. Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A, Mitan SJ. Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer's dementia. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville. 2000f:144.
61. Street JS, Clark WS, Juliar BI, Feldman PD, Kadam DI, Breirer A. Long-term efficacy of olanzapine in the control of psychotic and behavioural symptoms in patients with alzheimer's dementia. International Journal of Neuropsychopharmacology 2000d;3(Suppl 1):S356.
62. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Breier A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. International Journal of Geriatric Psychiatry 2001b;16(Suppl 1):S62-70.
63. Street JS/Clark SW, Juliar EJ, Feldman PD, Kadam DL, Breier A. Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia. Neurology 2000e;54(Suppl 2):A414.
64. Sutton G, Mintzer JE, Breier A, Clark WS, Feldman D, Street JS. Olanzapine in the treatment of anxiety in patients with alzheimer's disease. Schizophrenia Research 2001;49(Suppl 1-2):247.
65. Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, Degenhardt EK, Breier A. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. American Journal of Geriatric Psychiatry 2005;13(8):722-730.
66. Eli Lilly Inc. Olanzapine versus Risperidone and Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia. http//www.ifpma.org/clinicaltrials.html 2005:1-38.
67. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 2004;19(2):115-26.
68. DeDeyn P. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17-22, 1997. 1997a:10.
69. DeDeyn P, Lemmens P, De Smedt D. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13, Davos, Switzerland 1998c;29(1,2):145.
70. DeDeyn P, Lemmens P, De Smedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 21st Collegium Internationale Neuropsychopharmacologium (CINP) Congress; 1998 Jul 12-16 Glasgow, Scotland. 1998a:ABSTRACT REF: PW11025.
71. DeDeyn P, Lemmens P, De Smedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 December 8-12, Waikoloa, Hawai, USA. 1997b.
72. DeDeyn P, Middelheim AZ, De Smedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 10th European College of Neuropsychopharmacology Congress (ECNP); 1997 Sep 13-17, Vienna, Austria. 1997.
73. DeDeyn PP, De Smedt G. Long-term safety and efficacy of risperidone in the treatment of behavioral disturbances in elderly patients with dementia. Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31-Nov 4, Paris. 1998b:Abstract: P4007.
74. DeDeyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999a;53(5):946-55.
75. Lemmens P, DeDyne P, DeSmedt G. Risperidone in the treatment of behavioral disturbances in dementia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4, Toronto, Canada. 1998:160.
76. Colon S, Figueroa C, Thein S, Siegal A, Arias B, De La Ganadara J, Haefner G, Segal S, Steen S, Blanchette P, Mee-Lee D, Lindahl L, Rappaport SA, Kelsh D, Rayner A, Litman R, Shua-Haim J, Brenner R, Calder C, Sloan B, Gupta S, Lantz M, Levy M, Lebadeva Z, Patel M, Beckett L, Cranmer K, Richter R, Ainslie G, Rosenzweig A, Mintzer J, Fuller W, Gwirtsman H, Petrie W, Barnhart B, Demmler RW, Fedro D, Frank HD, Gazda S, Lewis R, Peters P, Schiffer R, Weiner M, Williams B, Winston J, Swerdlow R, RIS-USA-232. Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer's disease. Clinical Trials Journal 2002:1-6.
77. Brecher M. Follow-up study of risperidone in the treatment of patients with dementia: Interim results on tardive dyskinesia and dyskinesia severity. Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31-Nov 4, Paris. 1998a:Abstract: P4005.
78. Brecher M. Nursing home research from industry's perspective. International Psychogeriatrics 1996;8(Suppl 3):367-70.
79. Brecher M, Clyde C, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17-22, 1997. 1997:10.
80. Brecher M, Katz I, Clyde C, The Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior. Proceedings of the 21st Collegium Internationale Neuropsychopharmacologium (CINP) Congress; 1998 Jul 12-16 Glasgow, Scotland. 1998b.
81. Brecher M, Okamoto A, Napolitano J, Kane JM, Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. American Journal of Geriatric Psychiatry 1999a;7(4):53-4.
82. Brecher M, Okamoto A, Napolitano J, Kane JM, The Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperdione for up to one year. Schizophrenia Research 1999b;1,2 & 3:362.
83. DeDeyn PP, DeSmedt G. Efficacy and safety of risperidone in elderly patients with dementia pooled results from phase III controlled trials. Proceedings of the 40th Annual meeting of the new clinical drug evalution unit, Boca Raton, Florida, USA, May 30-June 2, 2000. 2000b.
84. Grossman F, Gharabawi G. Elderly patients with dementia and psychosis treated with risperidone. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva. 2002a:194.
85. Grossman F, Gharabawi G. Elderly patients with dementia and psychosis treated with risperidone. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002b:Abstract No 299.
86. Janssen Pharmaceutica. Low dose risperidone helps overcome burden of Alzheimer's disease. Pharmacoeconomics 1997;143:10.
87. Katz I, Brecher M, Clyde C, Jeste D, Mintzer J, Napolitano J, The Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8-11, San Diego, California. 1998.
88. Katz I, Brecher M, Clyde C, Napolitano J, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13, Davos, Switzerland 1998a;29(1,2):145.
89. Katz I, Brecher M, Clyde C, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 December 8-12, Waikoloa, Hawai, USA. 1997:292.
90. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Journal of Clinical Psychiatry 1999;60(2):107-15.
91. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher MB, Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4, Toronto, Canada. 1998b:156.
92. Mintzer J. Pharmacological treatment of nonagressive agitated symptoms related to dementia: analysis of 617 patients in a multicenter placebo-controlled study. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002:Abstract No 336.
93. Schneider L, Katz IR, Napolitano J, Martinez R, Azen SP. Psychosis of Alzheimer's disease: validity of the construct, and response to risperidone. Research and practice in Alzheimer's disease 2004;9(2004):153-9.
94. Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. American Journal of Geriatric Psychiatry 2003a;11(4):414-25.
95. Astrazeneca 1. Additional results presented. http://www.astrazeneca.com/pressrelease/2577.aspx 2004.
96. Astrazeneca 2. Study suggests potential benefits in agitation associated with dementia. http://www.astrazeneca.com/ 2004.
97. Tariot P. Medication helps quell the agitation of dementia. http://www.urmc.rochester.edu/pr/news/story.cfm?id=593 2004f.
98. Kujawa MJ, Marcus R, Breder C, Kostic D, Archibald DG, Iwamoto T, Carson WH, Yamamoto Y, Bristol-Myers Squibb Company, Plainsboro, NJ, USA. Safety and Tolerability Profile of Aripiprazole in Elderly Patients With Psychosis of Alzheimer's Disease: A Pooled Analysis. NeuroBiology of Aging 2004;25(S2):183.
99. Streim J, Breder C, Swanink R, McQuade R, Iwamoto T, Carson W, Stock E, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Flexible-Dose Aripiprazole in Psychosis of Alzheimer's Disease. NeuroBiology of Aging 2004;25(S2):191.
100. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. Journal of clinical psychiatry, The 2004i;65 Suppl 11:11-5.
101. Allain H, Tessier T, Bentue-Ferrer D, et al. Effects of Risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology (Berl) 2003;165(4):419-429.
102. Beuzen JN, Taylor N, Wesnes K, Wood A. comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. Journal of Psychopharmacology (Oxf) 1999;13(2):152-158.
103. Cassidy EL, Sheikh JI. Specific interventions for agitation in Alzheimer's disease. ClinicalTrials.gov 2001.
104. Chan WC, Lam LCW, Choy CNP, Leung VPY, Li SW, Chiu HFK. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16(12):1156-62.
105. Onalaja D, Jainer AK. Re: Chan et al A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. author reply. International Journal of Geriatric Psychiatry 2002;17(11):1076-77.
106. Davidson M. Long-term safety of risperidone. Journal of Clinical Psychiatry 2001;62(Suppl 21):26-28.
107. Defilippi JL, Crismon ML. Antipsychotic agents in patients with dementia. Pharmacotherapy 2000; Vol. 20, issue 1:23-33.
108. Devanand DP. Antipsychotic treatment in outpatients with dementia. International Psychogeriatrics 1996;8(Suppl 3):355-61.
109. Devanand, DP, Michaels K, Sackeim HA, Marder K, Mayeux RP. Antipsychotics in the treatment of dementia complicated by Psychosis. Conference proceedings 151st Annual Meeting of the American Psychiatric Association.; 30th May-4th June, 1998; Toronto, Ontario, Canada. 1998:No. 27D.
110. Ebell M. Which is most effective for managing the behavioral symptoms of dementia: risperidone or haloperidol?. Evidence-Based-Practice 2000;3(1):2-3.
111. Clinical Study Summary: Study F1D-MC-HGHX.
112. Fontaine CS, Hynan LS, Koch K, Martin Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Journal of Clinical Psychiatry 2003;64(6):726-30.
113. Buckley P, Cutler N, Silber C, O'Neil J, Mack R. The safety and tolerability of Sertindole in elederly patients with dementia. Schizophrenia Research 1997;24(1-2):201.
114. Cutler N, Sramek J, Kurtz N, Jhee S, O'Neil I, Mack R. The safety and tolerability of Sertindole in Elderly Patients with Dementia. Proceedings of the 10th Annual Meeting and Symposium of the American Academy of Geriatric Psychiatry; 1997 Mar 2-5, Orlando. 1997:3.
115. Grossberg GT, Cutler NR, Silber C, O'Neil J, Mack R. Sertindole Treatment in Elderly Patients with Dementia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22, San Diego. 1997.
116. Hoeltmann BJ, Delius-Stute H, Rettig K, Schwalen S. Less daytime sedation, dizziness and abnormal gait under risperidone in comparison with melperone. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002:Abstract No 347.
117. Howard R, Bullock R, Burns A, Lindesay J, O'Brien JT. The CALM-AD trial - a randomised clinical trial of a cholinesterase inhibitor and atypical antipsychotic in the management of agitation in dementia. National Research Register.
118. Jones B, Wang H, David SR, Nisivoccia JR, Beasley CM, Meehan KM. A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10-14, San Juan, Puerto Rico. 2000:190.
119. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. American Journal of Geriatric Psychiatry 1998; Vol. 6, issue 2:127-35.
120. Legangneux E, McEwen J, Wesnes K, et al. Effects of low doses of amisulpride on psychomotor and memory performances in healthy elderly subjects. Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31-Nov 4, Paris. 1998:Abstr P.2.004.
121. McKeith IG, Daniel S, Ballard CG, Swann A, Fairbairn AF, Perry EK. Recent advances in therapy in dementia with lewy bodies. Proceedings of the International Psychogeriatric Association Conference (Non-Alzheimer Cognitive Impairment); 2000 Apr 4-7, Newcastle upon Tyne. 2000.
122. Jones B, Wang H, David SR, Nisivoccia JR, Beasley CM, Meehan KM. A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10-14, San Juan, Puerto Rico. 2000:190.
123. Meehan KM, Wang H, David JR, Nisivoccia, Jones B, Beasley CM, Fieldman A, Breier A. A double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine and lorazepam in acutley agitated patients with dementia. Journal of the American Geriatrics Society 2001b;49(4):S92.
124. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Breier A. A double-blind, placebo-controlled study of intramuscular (IM) olanzapine and IM lorazepam in acutely agitated patients with dementia. Biological Psychiatry 2001a;49(8 Suppl 1):55S.
125. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26(4):494-504.
126. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Feldman PD, Breier A. A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco. 2001c.
127. Mintzer J, Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C Jr, Feldman P, Breier A. A double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002:Abstract No 133.
128. Meguro K, Meguro M, Tanaka Y, Akanuma K, Yamaguchi K, Itoh M. Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease. Journal of geriatric psychiatry and neurology 2004;17(2):61-7.
129. Mintzer J, Meehan K, Wang H, et al. A double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002, issue Abstr 133.
130. Parsa MA, Poggi E, Barte L. Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil. Journal of the European College of Neuropsychopharmacology. Proceedings of the 13th ECNP Congress; 2000 Jul 9-13, Munich 2000; Vol. 10, issue Suppl 3:S302.
131. Pesco-Koplowitz L, Parier JL, Zhao Q, Heron J. Pharmacokinetics of risperidone/donepezil combination. Biological Psychiatry 2000;47:167S.
132. Ruggiero U, Ovallesco V, Pizza V, Agresta A, Colucci D'amato C. Clozapine and validation therapy in the treatment of dementia. Functional Neurology 1997;12(3-4):240-1.
133. Slawson DC. Is olanzapine effective in the treatment of agitation/aggression and psychosis in patients with Alzheimer disease (AD)?. Evidence Based Practice 2001;4(1):5-6.
134. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-term use of quetiapine in elderly patients with psychotic disorder. Clinical-Therapeutics 2000; Vol. 22, issue 9:1068-84.
135. Weiser M, Davidson M, Rotmensch H, et al. A pilot randomized open-label trial assessing safety and pharmacokinetic parameters of co-adminstration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden. 2002:abstract 633.
136. Weiser M, Rotmensch HH, Korczyn AD, et al. A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. International Journal of Geriatric Psychiatry 2002;17(4):343-6.
137. Williams H, Clarke R, Bouras N, Martin J, Holt G. Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability. Journal of Intellectual Disability Research 2000; Vol. 44, issue 2:164-9.
138. Wolfgang SA. Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia [letter]. American Journal of Health System Pharmacy 1999;56(21):2245-6.
139. De Deyn PP, Brecher M, DeSmedt G. Risperidone in 969 patients with dementia. XI World Congress of Psychiatry, Hamburg, August 6-11, 1999. 1999b:Abstracts Volume II:70.
140. No information. Ongoing study Starting date of trial not provided. Contact author for more information.
141. Blanchard MR. Risperidone in the treatment of behavioural disturbances in dementia. National Research Register 2000.
142. No author. Risperidone vs Olanzapine vs Placebo (ORP): Alzheimer's Disease with Psychosis. John Hospkins University Clinical Trials Database 2000j. [MEDLINE: http:\\ww2.med.jhu.edu/jhhpsychiatry/gal.htm]
143. Anon. A study to evaluate Olanzapine for Alzheimer's disease. Centerwatch 2000n.
144. Anon. A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed with Dementia. Clinicaltrials.gov 2004i.
145. Pellegrino M. A 10-week, double-blind, comparative study evaluation of the effectiveness of Risperidone versus Olanzapine to placebo in patients with Alzheimer's Dementia. Centerwatch 2000. [MEDLINE: www.centerwatch.com/studies/stu13273.htm]
146. Ballard CG, Eastwood C, Gahir M, et al. A follow up study of depression in the carers of dementia sufferers. BMJ 1996;312:947.
147. Ballard CG, O'Brien JT. Pharmacological treatment of behavioural and psychological signs in Alzheimer's disease: how good is the evidence for current pharmacological treatment?. BMJ 1999;319:138-9.
148. Ballard CG, Ayre G, Gray A. Psychotic symptoms and behavioural disturbances in dementia: a review. Revue Neurologique 1999b;155(suppl 4):s44.
149. Ballard CG, O'Brien J, James I, et al. Quality of life for people with dementia living in nursing home and residential care. International Psychogeriatrics 2001;13:93-106.
150. Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L. CAMCOG--a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. British journal of clinical psychology 1995;34(Pt 4):529-41.
151. Chalmers TC, Celano P, Sacks HS, Smith H, Junior. Bias in Treatment Assignment in Controlled Clinical Trials. N Eng J Med 1983;309:1358-61.
152. Chouinard G, Ross-Chouinard A, Annable L, et al. The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences 1980;7:233.
153. Chief Medical Officer. New advice issued on risperidone and olanzapine. http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4075751&chk=f0tw6s 2004.
154. Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behaviour Mapping Instrument. International Psychogeriatrics 1996;8(suppl. 3):309-315.
155. Anon. New advice issued on risperidone and olanzapine. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON002047&ssTargetNodeId=389 2004.
156. Cummings JL, Mega M, Gray K. The Neuropsychiatric Inventory: Comprehensive Assessment of Psychopathology in Dementia. Neurology 1994;44:2308-2314.
157. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Press, 1994.
158. Food, Drug Administration. FDA Alert [4/11/2005]: Increased Mortality in Patients with Dementia-Related Psychosis. http://www.fda.gov/cder/drug/InfoSheets/HCP/risperidoneHCP.htm April 2005.
159. Furniss L, lloyd N, Craig SK, et al. Medication use in nursing homes for elderly. International Journal of Geriatric Psychiatry 1998;13:433-9.
160. Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer's disease. Journal of Neuropsychiatry 1991;3:371-376.
161. Guy W. Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration. NIMH Psychopharmacology Research Branch, 1976:218-22.
162. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organisation, Division of Mental Health, 1992.
163. Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds J, Gavaghan D, McQuay H. Assessing the quality of reports of randomised clinical trials: Is blinding necessary?. Controlled Clin Trials 1996;17:1-12.
164. Lonergan E, Luxenberg J, Colford J, Birks J. Haloperidol for agitation in dementia. The Cochrane Database of Systematic Reviews 2002, Issue 2 Art. No.: CD002852. DOI: 10.1002/14651858.CD002852.
165. McKeith IG, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-8.
166. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;4:939-44.
167. McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. BMJ 1997;314:211-2.
168. Mintzer JE. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. The Journal of Clinical Psychiatry 2001;62(suppl 21):23-25.
169. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook [updated 9 December 1996]. Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 1. Oxford: Update Software, 1997.
170. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. Journal of the American Medical Society 1982;248:333-5.
171. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-52.
172. Reisberg B. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. Journal of Clinical Psychiatry 1987;48(suppl. 5):9-15.
173. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society 1990;38:552-63.
174. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH and the Alzheimer's Disease Cooperative Group Study. Validity and reliability of the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change. Alzheimer Disease and Associated disorders 1997;11(suppl 2):S22-S32.
175. Schneider Ls, Dagerman KS Insel P. Risk of death with atypical antipsychotic drug treatment. Jouranl of the American Medical Association 2005;294(15):1934-1943.
176. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
177. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212(suppl 44):11-19.
178. Steele C, Rovner B, Chase BA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry 1990;147:1049-51.
179. Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioural symptoms of Alzheimer's disease. Psychiatr Clinics North Am 1991;14:353-73.
180. Waite J. Keep taking the medicine. Age and Ageing 2002;31(6):423-425. [MEDLINE: 12446286 Medline 20050101]
181. Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003476.pub2]